A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura

Inclusion Criteria:

- Have a diagnosis of episodic or chronic migraine as defined by International Headache
Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta
guidelines (1.1, 1.2 or 1.3) (ICHD-3 2013), with a history of migraine headaches of at
least 1 year prior to screening, and migraine onset prior to age 50.

- Prior to baseline, a history of 4 or more migraine headache days per month on average
for the past 3 months.

Exclusion Criteria:

- Are currently enrolled in or have participated within the last 30 days or within 5
half-lives (whichever is longer) in a clinical trial involving an investigational
product.

- Current use or prior exposure to galcanezumab or another CGRP antibody.

- Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
proteins, or to galcanezumab.

- History of persistent daily headache, cluster headache or migraine subtypes including
hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine
with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.